UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

European journal of cancer (1990), 2009-09, Vol.45, p.436-438

Takimoto, Chris H

2009

Volltextzugriff (PDF)

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Biochemistry (Easton), 1993-05, Vol.32 (18), p.4756-4760

1993

Volltextzugriff (PDF)

Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development

Clinical cancer research, 2010-10, Vol.16 (19_Supplement), p.PL6-1-PL6-1

Takimoto, Chris H.

2010

Volltextzugriff (PDF)

New Antifolates: Pharmacology and Clinical Applications

The oncologist (Dayton, Ohio), 1996-02, Vol.1 (1-2), p.68-81

Takimoto, Chris H.

1996

Volltextzugriff (PDF)

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

Blood, 2019-11, Vol.134 (Supplement_1), p.5229-5229

2019

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor and Other Molecular Targets in the Treatment of Cancer

Clinical colorectal cancer, 2003-02, Vol.2 (4), p.252-252

Takimoto, Chris H.

2003

Volltextzugriff (PDF)

Are there any better camptothecins than the ones we have?

Clinical advances in hematology & oncology, 2003-10, Vol.1 (10), p.578

Takimoto, Chris H

2003

Volltextzugriff (PDF)

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Blood, 2018-11, Vol.132 (Supplement 1), p.2327-2327

2018

Volltextzugriff (PDF)

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.2729-2729

2018

Volltextzugriff (PDF)

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

Blood, 2019-11, Vol.134 (Supplement_1), p.4428-4428

2019

Volltextzugriff (PDF)

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

Blood, 2019-11, Vol.134 (Supplement_1), p.569-569

2019

Volltextzugriff (PDF)

The clinical pharmacology of the oral fluoropyrimidines

Current problems in cancer, 2001-06, Vol.25 (3), p.134-213

Takimoto, Chris H

2001

Volltextzugriff (PDF)

Thymidylate synthase inhibitors

Cancer chemotherapy and biological response modifiers, 2005, Vol.22, p.1

2005

Volltextzugriff (PDF)

Abstract 3365: Population pharmacokinetics of oxaliplatin: An analysis across human development in infants, children and adults

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3365-3365

2013

Volltextzugriff (PDF)

Basic pharmacokinetics and pharmacodynamic principles

Cancer treatment and research, 2001, Vol.106, p.85

Takimoto, C H

2001

Volltextzugriff (PDF)

Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?

Nature clinical practice. Oncology, 2007-03, Vol.4 (3), p.152-153

Takimoto, Chris H

2007

Volltextzugriff (PDF)

Maximum tolerated dose: clinical endpoint for a bygone era?: Toxicities

Targeted oncology, 2009, Vol.4 (2), p.143-147

TAKIMOTO, Chris H

2009

Volltextzugriff (PDF)

Abstract A37: Development of biologics targeting soluble ligands: Novel biomarker and PK-PD analyzes examining free and total ligand profile following treatment with carlumab (anti-CCL2 mAb)

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A37-A37

2011

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-6432

Clinical cancer research, 2012-03, Vol.18 (10)

2012

Volltextzugriff (PDF)

Foreword

Current problems in cancer, 2006-01, Vol.30 (1), p.6

Takimoto, Chris H.

2006

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Blood, 2010-11, Vol.116 (21), p.3975-3975

2010

Volltextzugriff (PDF)

Foreword

Current problems in cancer, 2005-01, Vol.29 (1), p.7

Takimoto, Chris H.

2005

Volltextzugriff (PDF)

Identification of an RNA Binding Site for Human Thymidylate Synthase

Proceedings of the National Academy of Sciences - PNAS, 1993-01, Vol.90 (2), p.517-521

1993

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

Cancer chemotherapy and pharmacology, 2010, Vol.65 (1), p.167-175

2010

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

New Antifolates: Pharmacology and Clinical Applications

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

Epidermal Growth Factor Receptor and Other Molecular Targets in the Treatment of Cancer

Are there any better camptothecins than the ones we have?

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

The clinical pharmacology of the oral fluoropyrimidines

Thymidylate synthase inhibitors

Abstract 3365: Population pharmacokinetics of oxaliplatin: An analysis across human development in infants, children and adults

Basic pharmacokinetics and pharmacodynamic principles

Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?

Maximum tolerated dose: clinical endpoint for a bygone era?: Toxicities

Abstract A37: Development of biologics targeting soluble ligands: Novel biomarker and PK-PD analyzes examining free and total ligand profile following treatment with carlumab (anti-CCL2 mAb)

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-6432

Foreword

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Foreword

Identification of an RNA Binding Site for Human Thymidylate Synthase

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

Aktive Filter

Suchergebnisse filtern